Heterocyclic substituted pyrimidopyran compounds and uses thereof
Heterocyclic substituted pyrimidopyran compounds are developed to target KRASG12D mutations, addressing the lack of effective treatments for this mutation in cancer, thereby offering therapeutic benefits.
WO2026046397A1 Publication Date: 2026-03-05D3 BIO (WUXI) CO LTD
2 Cites 1 Cited by
Patent Information
- Application Number
- PCT/CN2025/118250
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-07-21
- Filing Date
- 2025-09-01
- Publication Date
- 2026-03-05
AI Technical Summary
Technical Problem
Current treatments for KRASG12D mutations in cancer have limited efficacy, necessitating the development of small molecule inhibitors to target this specific mutation for precision medicine.
Method used
Development of heterocyclic substituted pyrimidopyran compounds that act as inhibitors of mutated KRAS, particularly KRASG12D, for use in treating or preventing associated diseases.
Benefits of technology
The compounds effectively inhibit KRASG12D mutations, providing therapeutic benefits for cancer patients who have not responded to existing treatments.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates to a class of heterocyclic substituted pyrimidopyran compounds, such as a compound of Formula (I): or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and applications thereof.
Need to check novelty before this filing date? Find Prior Art